A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

This study is testing an experimental medicine called MBRC-201, which is a 'targeted therapy' designed to deliver medicine directly to cancer cells while sparing healthy ones. It is designed for people with advanced cancers that have not responded well to standard treatments, helping researchers find the safest and most effective dose.

This study is open to adults 18 and older with specific types of advanced cancer, including prostate, breast, lung, colon, or pancreatic cancer. You must be able to follow study instructions and follow strict birth control rules to ensure safety during the treatment period.

You will receive the experimental medicine MBRC-201 and be closely monitored by a team of doctors to see how your body reacts to the treatment. This helps the researchers learn if the medicine is safe and how it works against your specific type of cancer.

The study is currently recruiting volunteers at medical centers in San Francisco, CA; Grand Rapids, MI; and East Brunswick, NJ. Please speak with your doctor to see if one of these locations is right for you.